New hope for ovarian cancer: Rina-S faces off against chemo in major trial
NCT ID NCT07564141
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new drug or standard chemo. The main goal is to see if Rina-S can delay cancer growth better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rina-S (rinatabart sesutecan) with or without bevacizumab
What this could lead to
If successful, this could offer a new treatment option for women with recurrent platinum-sensitive ovarian cancer, potentially improving how long the cancer stays under control.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not work better than standard chemotherapy, and side effects could be similar or different.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••